NCT03950570: ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

NCT03950570
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed through at least 2 lines of therapy 
Exclusions: Patients with known active uncontrolled or symptomatic brain metastases- stable brain metastases may be enrolled- see trial for details
https://ClinicalTrials.gov/show/NCT03950570

Comments are closed.

Up ↑